Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens.

Athanasiou E, Kaloutsi V, Kotoula V, Hytiroglou P, Kostopoulos I, Zervas C, Kalogiannidis P, Fassas A, Christakis JI, Papadimitriou CS.

Am J Clin Pathol. 2001 Oct;116(4):535-42.

PMID:
11601138
2.

In situ hybridization and reverse transcription-polymerase chain reaction for cyclin D1 mRNA in the diagnosis of mantle cell lymphoma in paraffin-embedded tissues.

Athanasiou E, Kotoula V, Hytiroglou P, Kouidou S, Kaloutsi V, Papadimitriou CS.

Mod Pathol. 2001 Feb;14(2):62-71.

3.

Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.

Specht K, Kremer M, Müller U, Dirnhofer S, Rosemann M, Höfler H, Quintanilla-Martinez L, Fend F.

Clin Cancer Res. 2002 Sep;8(9):2902-11.

4.

Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.

Markovic O, Marisavljevic D, Cemerikic V, Suvajdzic N, Milic N, Colovic M.

Med Oncol. 2004;21(1):73-80.

PMID:
15034217
5.
6.

Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections.

Vasef MA, Medeiros LJ, Yospur LS, Sun NC, McCourty A, Brynes RK.

Mod Pathol. 1997 Sep;10(9):927-32.

PMID:
9310957
7.

Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.

Wilson CS, Butch AW, Lai R, Medeiros LJ, Sawyer JR, Barlogie B, McCourty A, Kelly K, Brynes RK.

Br J Haematol. 2001 Mar;112(3):776-82.

PMID:
11260083
8.

A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.

Yufu Y, Goto T, Choi I, Uike N, Kozuru M, Ohshima K, Taniguchi T, Motokura T, Yatabe Y, Nakamura S.

Cancer. 1999 Apr 15;85(8):1750-7.

PMID:
10223569
9.

The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.

Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, Klein B, Brochier J.

Hum Pathol. 1999 Dec;30(12):1405-11.

PMID:
10667416
10.

Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels.

Specht K, Haralambieva E, Bink K, Kremer M, Mandl-Weber S, Koch I, Tomer R, Hofler H, Schuuring E, Kluin PM, Fend F, Quintanilla-Martinez L.

Blood. 2004 Aug 15;104(4):1120-6. Epub 2004 Apr 13.

11.

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Bonifazi F, Neri A, Fabris S, Tura S, Baccarani M, Martinelli G.

Blood. 2003 Sep 1;102(5):1588-94. Epub 2003 May 1.

12.

Bcl-1 rearrangement and cyclin D1 protein expression in multiple myeloma precursor cells.

Liu X, Tang Z, Zou P.

J Tongji Med Univ. 2000;20(2):128-31, 136.

PMID:
12845725
13.

A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas.

Belaud-Rotureau MA, Parrens M, Dubus P, Garroste JC, de Mascarel A, Merlio JP.

Mod Pathol. 2002 May;15(5):517-25.

14.

Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.

Quintanilla-Martinez L, Kremer M, Specht K, Calzada-Wack J, Nathrath M, Schaich R, Höfler H, Fend F.

Am J Pathol. 2003 May;162(5):1449-61.

15.

The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.

Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ.

Am J Clin Pathol. 2000 Jun;113(6):831-7.

PMID:
10874884
16.

Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma.

Rasmussen T, Knudsen LM, Johnsen HE.

Eur J Haematol. 2001 Nov-Dec;67(5-6):296-301.

PMID:
11872077
17.

Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

Pruneri G, Fabris S, Baldini L, Carboni N, Zagano S, Colombi MA, Ciceri G, Lombardi L, Rocchi M, Buffa R, Maiolo AT, Neri A.

Am J Pathol. 2000 May;156(5):1505-13.

18.

Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.

Cook JR, Hsi ED, Worley S, Tubbs RR, Hussein M.

Am J Clin Pathol. 2006 Apr;125(4):615-24.

PMID:
16627271
19.

Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas.

Medeiros LJ, Hai S, Thomazy VA, Estalilla OC, Romaguera J, Luthra R.

Mod Pathol. 2002 May;15(5):556-64.

20.

Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance.

Marković O, Marisavljević D, Cemerikić V, Vidović A, Perunicić M, Todorović M, Elezović I, Colović M.

Med Oncol. 2008;25(4):451-7. doi: 10.1007/s12032-008-9066-y. Epub 2008 May 1.

PMID:
18449811

Supplemental Content

Support Center